Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Viral nucleic acid refers to the genetic material of a virus, which can be either DNA or RNA but never both in the same virion. The nucleic acid carries the instructions necessary for the production of viral proteins and the replication of the virus within a host cell. Viral nucleic acids are encapsulated within a proteinaceous capsid and, in some cases, an additional lipid envelope. Antiviral therapies often target viral nucleic acids directly (via nucleoside analogs that cause chain termination during replication) or indirectly by inhibiting viral enzymes responsible for synthesizing new viral genetic material. Because "viral nucleic acid" is a class term inclusive of many different genome types, it is not a precise therapeutic target but remains a central concept in virology and antiviral drug design[1][3][4][5][7].
Chain termination during replication (nucleoside/tide analogs) - Inhibition of viral RNA/DNA-directed polymerases - Disruption of RNA structure/translation (direct RNA binders)[2][10] - Inhibition of viral genome integration (for retroviruses)
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Viral nucleic acid.